Generics in Australia

December 2025 | 44 pages | ID: GB306776CEFEN
MarketLine

Abstracts

Generics in Australia industry profile provides top-line qualitative and quantitative summary information including: market share, market size (value and volume 2019-24, and forecast to 2029). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.
Key Highlights

• A generic drug is defined as a copy of an ethical (prescription) drug formerly protected by patents that have now expired. Both unbranded generics and branded generics are included in our market scope. However, off-patent drugs that continue to be offered by the original manufacturer under the original name, and which form part of the 'generic-eligible' market, are not included. Market value is evaluated at ex-factory prices. Market volume refers to the proportion of the total ethical pharmaceutical market in a country or region that is made up of generic drugs. Thus, it is a measure of the market share held by generics, rather than a direct measure of the total market volume. Regional volumes are calculated as averages of countries that comprise the region where volume data exists.
• The Australian generics market recorded revenues of $2.3 billion in 2024, representing a compound annual growth rate (CAGR) of 6.3% between 2019 and 2024.
• Market consumption volume increased with a CAGR of 4.3% between 2019 and 2024, reaching a total of 80.8% of total pharma volume in 2024.
• In 2024, the revenue of the Australian generics market experienced an annual growth of 6.3%. The market’s growth is driven by the rising prevalence of chronic diseases such as diabetes, hypertension, and cardiovascular conditions, increasing the demand for affordable, long-term medications.

Scope

• Save time carrying out entry-level research by identifying the size, growth, major segments, and leading players in the generics market in Australia
• Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the generics market in Australia
• Leading company profiles reveal details of key generics market players’ global operations and financial performance
• Add weight to presentations and pitches by understanding the future growth prospects of the Australia generics market with five year forecasts by both value and volume

Reasons to Buy

• What was the size of the Australia generics market by value in 2024?
• What will be the size of the Australia generics market in 2029?
• What factors are affecting the strength of competition in the Australia generics market?
• How has the market performed over the last five years?
• Who are the top competitors in Australia's generics market?

Contents

1 EXECUTIVE SUMMARY

1.1. Market value
1.2. Market value forecast
1.3. Market volume
1.4. Market volume forecast
1.5. Geography segmentation
1.6. Market rivalry
1.7. Competitive landscape

2 MARKET OVERVIEW

2.1. Market definition
2.2. Market analysis

3 MARKET DATA

3.1. Market value
3.2. Market volume

4 MARKET SEGMENTATION

4.1. Geography segmentation

5 MARKET OUTLOOK

5.1. Market value forecast
5.2. Market volume forecast

6 FIVE FORCES ANALYSIS

6.1. Summary
6.2. Buyer power
6.3. Supplier power
6.4. New entrants
6.5. Threat of substitutes
6.6. Degree of rivalry

7 COMPETITIVE LANDSCAPE

7.1. Who are the leading players?
7.2. What strategies do the leading players follow?
7.3. What are the strengths of the leading players?

8 COMPANY PROFILES

8.1. Teva Pharmaceutical Industries Ltd
8.2. Viatris Inc
8.3. Aspen Pharmacare Holdings Ltd
8.4. Lupin Ltd

9 MACROECONOMIC INDICATORS

9.1. Country data

10 APPENDIX

10.1. Methodology
10.2. Industry associations
10.3. Related MarketLine research
10.4. About MarketLine

List Of Tables

LIST OF TABLES

Table 1: Australia generics market value: $ million, 2019-24
Table 2: Australia generics market volume: % of total pharma volume, 2019-24
Table 3: Australia generics market geography segmentation: $ million, 2024
Table 4: Australia generics market value forecast: $ million, 2024-29
Table 5: Australia generics market volume forecast: % of total pharma volume, 2024-29
Table 6: Teva Pharmaceutical Industries Ltd: Key Facts
Table 7: Teva Pharmaceutical Industries Ltd: Annual Financial Ratios
Table 8: Teva Pharmaceutical Industries Ltd: Key Employees
Table 9: Viatris Inc: Key Facts
Table 10: Viatris Inc: Annual Financial Ratios
Table 11: Viatris Inc: Key Employees
Table 12: Aspen Pharmacare Holdings Ltd: Key Facts
Table 13: Aspen Pharmacare Holdings Ltd: Annual Financial Ratios
Table 14: Aspen Pharmacare Holdings Ltd: Key Employees
Table 15: Lupin Ltd: Key Facts
Table 16: Lupin Ltd: Annual Financial Ratios
Table 17: Lupin Ltd: Key Employees
Table 18: Australia Size of Population (Million), 2020-24
Table 19: Australia Real GDP (Constant 2010 Prices, $ Billion), 2020-24
Table 20: Australia GDP (Current Prices, $ Billion), 2020-24
Table 21: Australia Inflation, 2020-24
Table 22: Australia Consumer Price Index (Absolute), 2020-24
Table 23: Australia Exchange Rate, 2019-24

List Of Figures

LIST OF FIGURES

Figure 1: Australia generics market value: $ million, 2019-24
Figure 2: Australia generics market volume: % of total pharma volume, 2019-24
Figure 3: Australia generics market geography segmentation: % share, by value, 2024
Figure 4: Australia generics market value forecast: $ million, 2024-29
Figure 5: Australia generics market volume forecast: % of total pharma volume, 2024-29
Figure 6: Forces driving competition in the generics market in Australia, 2024
Figure 7: Drivers of buyer power in the generics market in Australia, 2024
Figure 8: Drivers of supplier power in the generics market in Australia, 2024
Figure 9: Factors influencing the likelihood of new entrants in the generics market in Australia, 2024
Figure 10: Factors influencing the threat of substitutes in the generics market in Australia, 2024
Figure 11: Drivers of degree of rivalry in the generics market in Australia, 2024